Are analysts optimistic about Recursion Pharmaceuticals Inc.’s (NASDAQ:RXRX) stock?

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed the day trading at $8.71 up 0.69% from the previous closing price of $8.65. In other words, the price has increased by $+0.06 from its previous closing price. On the day, 1105448 shares were traded. RXRX stock price reached its highest trading level at $8.95 during the session, while it also had its lowest trading level at $8.28.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



For a better understanding of RXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.80 and its Current Ratio is at 5.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, KeyBanc Capital Markets on September 16, 2022, initiated with a Overweight rating and assigned the stock a target price of $20.

On April 18, 2022, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $10.

SVB Leerink Downgraded its Outperform to Mkt Perform on March 04, 2022, while the target price for the stock was maintained at $10.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 when Virani Shafique sold 10,000 shares for $9.16 per share. The transaction valued at 91,561 led to the insider holds 73,160 shares of the business.

Mubadala Investment Co PJSC bought 69,518 shares of RXRX for $536,846 on Jan 10. The 10% Owner now owns 12,321,732 shares after completing the transaction at $7.72 per share. On Jan 10, another insider, Borgeson Blake, who serves as the Director of the company, sold 8,885 shares for $7.69 each. As a result, the insider received 68,283 and left with 7,620,712 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 56.33 while its Price-to-Book (P/B) ratio in mrq is 3.89.

Stock Price History:

Over the past 52 weeks, RXRX has reached a high of $14.18, while it has fallen to a 52-week low of $4.92. The 50-Day Moving Average of the stock is 8.90, while the 200-Day Moving Average is calculated to be 8.86.

Shares Statistics:

Over the past 3-months, RXRX traded about 1.26M shares per day on average, while over the past 10 days, RXRX traded about 962.9k shares per day. A total of 173.44M shares are outstanding, with a floating share count of 168.82M. Insiders hold about 5.50% of the company’s shares, while institutions hold 68.70% stake in the company. Shares short for RXRX as of Oct 13, 2022 were 15.55M with a Short Ratio of 16.78M, compared to 14.39M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.98% and a Short% of Float of 13.23%.

Earnings Estimates

Current recommendations for the stock of the company come from 4 analysts. On average, analysts expect EPS of -$0.38 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.43, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.11 and low estimates of -$0.49.

Analysts are recommending an EPS of between -$1.17 and -$1.76 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.58, with 5 analysts recommending between -$1.24 and -$2.02.

Revenue Estimates

4 analysts predict $6.97M in revenue for the current quarter. It ranges from a high estimate of $8M to a low estimate of $5.6M. As of the current estimate, Recursion Pharmaceuticals Inc.’s year-ago sales were $2.53M, an estimated increase of 175.10% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $30.15M, an increase of 1,090.30% over than the figure of $175.10% in the same quarter last year. There is a high estimate of $63M for the next quarter, whereas the lowest estimate is $8M.

A total of 5 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83M, while the lowest revenue estimate was $28.81M, resulting in an average revenue estimate of $48.56M. In the same quarter a year ago, actual revenue was $10.18M, up 377.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $63.34M in the next fiscal year. The high estimate is $121M and the low estimate is $35M. The average revenue growth estimate for next year is up 30.40% from the average revenue estimate for this year.